Cost-effectiveness analysis of atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in advanced hepatocellular carcinoma in Singapore.
Saved in:
| Title: | Cost-effectiveness analysis of atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in advanced hepatocellular carcinoma in Singapore. |
|---|---|
| Authors: | Chee CE; Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS), National University Health System, Singapore, Singapore., Khara JS; Medical, Roche Singapore Pte Ltd, Singapore, Singapore., Cheong J; Market Access, Roche Singapore Pte Ltd, Singapore, Singapore., Fong J; Market Access, Roche Singapore Pte Ltd, Singapore, Singapore., Sivanesan S; Medical, Roche Singapore Pte Ltd, Singapore, Singapore., Choy JY; Market Access and Health Economics, Costello Medical Singapore Pte Ltd, Singapore, Singapore., Hu M; Market Access and Health Economics, Costello Medical Singapore Pte Ltd, Singapore, Singapore., Viswambaram A; Market Access and Health Economics, Costello Medical Singapore Pte Ltd, Singapore, Singapore., Toh HC; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore. |
| Source: | Expert review of pharmacoeconomics & outcomes research [Expert Rev Pharmacoecon Outcomes Res] 2024 Jun; Vol. 24 (5), pp. 631-641. Date of Electronic Publication: 2024 May 22. |
| Publication Type: | Journal Article; Comparative Study |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 101132257 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8379 (Electronic) Linking ISSN: 14737167 NLM ISO Abbreviation: Expert Rev Pharmacoecon Outcomes Res Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 38776431 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Cost-effectiveness analysis of atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in advanced hepatocellular carcinoma in Singapore. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Chee+CE%22">Chee CE</searchLink>; Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS), National University Health System, Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Khara+JS%22">Khara JS</searchLink>; Medical, Roche Singapore Pte Ltd, Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Cheong+J%22">Cheong J</searchLink>; Market Access, Roche Singapore Pte Ltd, Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Fong+J%22">Fong J</searchLink>; Market Access, Roche Singapore Pte Ltd, Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Sivanesan+S%22">Sivanesan S</searchLink>; Medical, Roche Singapore Pte Ltd, Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Choy+JY%22">Choy JY</searchLink>; Market Access and Health Economics, Costello Medical Singapore Pte Ltd, Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Hu+M%22">Hu M</searchLink>; Market Access and Health Economics, Costello Medical Singapore Pte Ltd, Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Viswambaram+A%22">Viswambaram A</searchLink>; Market Access and Health Economics, Costello Medical Singapore Pte Ltd, Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Toh+HC%22">Toh HC</searchLink>; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101132257%22">Expert review of pharmacoeconomics & outcomes research</searchLink> [Expert Rev Pharmacoecon Outcomes Res] 2024 Jun; Vol. 24 (5), pp. 631-641. <i>Date of Electronic Publication: </i>2024 May 22. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Comparative Study – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Taylor+%26+Francis%22">Taylor & Francis </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101132257 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1744-8379 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214737167%22">14737167 </searchLink><i>NLM ISO Abbreviation: </i>Expert Rev Pharmacoecon Outcomes Res <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38776431 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1080/14737167.2024.2319607 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 631 Titles: – TitleFull: Cost-effectiveness analysis of atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in advanced hepatocellular carcinoma in Singapore. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Chee CE – PersonEntity: Name: NameFull: Khara JS – PersonEntity: Name: NameFull: Cheong J – PersonEntity: Name: NameFull: Fong J – PersonEntity: Name: NameFull: Sivanesan S – PersonEntity: Name: NameFull: Choy JY – PersonEntity: Name: NameFull: Hu M – PersonEntity: Name: NameFull: Viswambaram A – PersonEntity: Name: NameFull: Toh HC IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 06 Text: 2024 Jun Type: published Y: 2024 Identifiers: – Type: issn-electronic Value: 1744-8379 Numbering: – Type: volume Value: 24 – Type: issue Value: 5 Titles: – TitleFull: Expert review of pharmacoeconomics & outcomes research Type: main |
| ResultId | 1 |
